Company / R&D Expense
LeMaitre Vascular R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$14.1M
FY2025
5-year range
$9.3M / $17.0M
FY2021-FY2025
Trend
-9.7%
vs FY2024
Sector context
#102 of 110
Health Care
What the data says
Among 110 Health Care companies, LeMaitre Vascular is in the bottom 7% for r&d expense. Declined from $17M to $14M over the past 2 years.
Based on SEC 10-K filings.
$14M in FY2025 with a 5-year CAGR of +11.5%.
Declined from $17M to $14M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +11.9%
- 5-Year CAGR
- +11.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 110This company $14.1M Sector average $298.2M
▼
-95.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +11.5%, indicating consistent growth.
- In FY2025, r&d expense decreased 9.7% year-over-year.
- Ranks #102 out of 110 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Strong profit margin: 20.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $14.1M | -9.7% |
| FY2024 | $15.7M | -7.8% |
| FY2023 | $17.0M | +68.0% |
| FY2022 | $10.1M | +8.9% |
| FY2021 | $9.3M | +13.2% |
| FY2020 | $8.2M | +23.5% |
| FY2019 | $6.6M | +8.1% |
| FY2018 | $6.1M | +12.1% |
| FY2017 | $5.5M | -10.8% |
| FY2016 | $6.1M | +17.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026